On the other hand, if we are looking at US based cornerstone investors ( which I find increasingly likely ) there is also the possibility that such placement is done at a premium price with such diversified outlook for neurodegenerative diseases.
That option would though also explain the cap in place.
all IMO
On the other hand, if we are looking at US based cornerstone...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.0¢ | $405.7K | 3.847M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 744009 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 14061 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |